



JOINT TRANSNATIONAL CALL 2017:

"Translational research on rare cancers" PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to

If you have any questions about this form, please do not hesitate to contact us at

Note: Fields marked with a * are mandatory

Contact Information	
First name *	Rene
Last name *	Rodríguez
Position *	Principal Investigator
Telephone number	+34 985107956
E-mail address*	rodriguezrene.uo@uniovi.es
Website address	https://www.unioviedo.es/IUOPA/?page_id=2&lang=es
Institution/Organisation *	Central University Hospital of Asturias (HUCA), Spain
Department*	Institute of Oncology of Asturias (IUOPA) / Institute of Health Research of Asturias (ISPA)
Street	Av. de Roma, s/n
Postal Code / City *	33011 / Oviedo
Country *	Spain

***I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:**

YES



SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

Project proposal

Project title (draft):

Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words):



OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

Short description of the areas of interest and expertise (Max. 2000 words):

INVESTIGATION ON DRUG RESPONSE IN SARCOMAS USING TRANSLATIONAL RESEARCH PLATFORMS

The Sarcoma and Cancer Stem Cell Group of the Institute of Health Research of Asturias -Central University Hospital of Asturias (ISPA-HUCA) in Oviedo, Spain, is interested in joining a research consortium that is willing to participate in the call JTC 2017 of the ERA-NET TRANSCAN 2018 presenting a project in the topic of *drug response/resistance and toxicity in sarcomas using translational research platforms* (aim 2 of the Call).

This group would be able to contribute to the consortium with the following resources and/or research expertise:

- The group has access to **fresh tumor tissue from sarcoma patients** operated in the HUCA (obtained upon signed informed consent). Using this material the group has already obtained and characterized a collection of more than 15 primary-derived (low passaged) cell lines, and the research group is currently working on additional cell lines. The team is currently focused on the study of **chondrosarcoma, liposarcoma, osteosarcoma and pleomorphic undifferentiated sarcoma**, although we may provide material of many **other sarcoma types**.
- The group has fresh tissue frozen in conditions that allow the establishment of **PDXs**.
- The group has experience in **3D-cultures** and may develop if needed 3D-organoids derived from fresh patient-derived tumor tissue.
- The group has experience in the **characterization of CSC subpopulations in sarcoma** and also in analyzing the effect of anti-tumor drugs in such subpopulations.
- Several **drugs with anti-tumor effects on sarcoma CSCs** may be provided.

Recent publications of the group on this topic are:

1. Martinez-Cruzado L, et al. Trabectedin and Camptothecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models. *Neoplasia*. 2017 Jun;19(6):460-470. doi: 10.1016/j.neo.2017.03.004.
2. Martinez-Cruzado L, et al. Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations. *Sci Rep*. 2016 Jun 13;6:27878. doi: 10.1038/srep27878.
3. Tornin J, et al. Inhibition of SP1 by the mithramycin analog EC-8042 efficiently targets tumor initiating cells in sarcoma. *Oncotarget*. 2016 May 24;7(21):30935-50. doi:10.18632/oncotarget.8817.

Further information on the research that has been developed and is currently ongoing can be requested via e-mail at rodriguezrene.uo@uniovi.es or renerg.finba@gmail.com.